Citation: | ZHANG Baizhong, HAN Qing, MA Chunyuan. Investigation in serum minerals and bone disorder in patients with chronic kidney disease at stages 5 and 5D[J]. Journal of Clinical Medicine in Practice, 2021, 25(4): 89-92. DOI: 10.7619/jcmp.20200838 |
[1] |
MA Y C, ZUO L, CHEN J H, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease[J]. J Am Soc Nephrol, 2006, 17(10): 2937-2944. doi: 10.1681/ASN.2006040368
|
[2] |
全国eGFR课题协作组. MDRD方程在我国慢性肾脏病患者中的改良和评估[J]. 中华肾脏病杂志, 2006(10): 589-595. doi: 10.3760/j.issn:1001-7097.2006.10.002
|
[3] |
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J]. Kidney Int Suppl, 2009(113): S1-130. http://www.ncbi.nlm.nih.gov/pubmed/19644521
|
[4] |
FUKAGAWA M, YOKOYAMA K, KOIWA F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder[J]. Ther Apher Dial, 2013, 17(3): 247-288. http://www.ncbi.nlm.nih.gov/pubmed/23735142
|
[5] |
Kidney disease: improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2017, 7(3): e1. doi: 10.1016/j.kisu.2017.10.001
|
[6] |
ROUACHED M, EL KADIRI BOUTCHICH S, AL RIFAI A M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease[J]. Kidney Int, 2008, 74(3): 389-390.
|
[7] |
马春园, 苑雪莹, 刘婧怡, 等. 慢性肾脏病-矿物质及骨代谢紊乱的单中心横断面研究[J]. 中华肾脏病杂志, 2015, 31(5): 333-338. doi: 10.3760/cma.j.issn.1001-7097.2015.05.003
|
[8] |
MELAMED M L, EUSTACE J A, PLANTINGA L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study[J]. Kidney Int, 2006, 70(2): 351-357. doi: 10.1038/sj.ki.5001542
|
[9] |
TENTORI F, BLAYNEY M J, ALBERT J M, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS)[J]. Am J Kidney Dis, 2008, 52(3): 519-530. doi: 10.1053/j.ajkd.2008.03.020
|
[10] |
DEBOWSKA M, WOJCIK-ZALUSKA A, KSIAZEK A, et al. Phosphate, urea and creatinine clearances: haemodialysis adequacy assessed by weekly monitoring[J]. Nephrol Dial Transplant, 2015, 30(1): 129-136. doi: 10.1093/ndt/gfu266
|
[11] |
COPLAND M, KOMENDA P, WEINHANDL E D, et al. Intensive hemodialysis, mineral and bone disorder, and phosphate binder use[J]. Am J Kidney Dis, 2016, 68(5): S24-S32. doi: 10.1053/j.ajkd.2016.05.024
|
[12] |
ZHU J G, CHEN J B, CHENG B C, et al. Association between extreme values of markers of chronic kidney disease: mineral and bone disorder and 5-year mortality among prevalent hemodialysis patients[J]. Blood Purif, 2018, 45(1/2/3): 1-7. http://www.karger.com/?DOI=10.1159/000478972
|
[13] |
VASSALOTTI J A, URIBARRI J, CHEN S C, et al. Trends in mineral metabolism: kidney early evaluation program (KEEP) and the national health and nutrition examination survey (NHANES)1999-2004[J]. Am J Kidney Dis, 2008, 51(4 Suppl 2): S56-S68. http://www.ncbi.nlm.nih.gov/pubmed/18359409
|